Cell & Gene Therapy Market Growing

The cell and gene therapy market is booming. By 2028, it’s expected to soar from $7.2 billion in 2023 to $23.3 billion, growing over 26% annually.

This rapid growth is driven by rising chronic disease cases, increased research funding, and more regulatory approvals.

What’s Fueling the Growth?

The market covers three main types of therapies:

• Cell therapy

• Gene therapy

• Gene-modified cell therapy

These therapies are used to treat rare diseases, cancer, and eye disorders. North America leads the market due to advanced technologies and strong infrastructure. Europe and Asia-Pacific are catching up, boosted by supportive regulations and growing investments.

Key Innovations

Breakthrough treatments like CAR-T cell therapies (e.g., Kymriah, Yescarta) and gene therapies for rare conditions (e.g., Zynteglo) are shaping the future. Partnerships between pharmaceutical giants and biotech firms are accelerating research and development.

Challenges

The market faces hurdles like high costs and the short shelf life of some therapies. Despite these issues, innovation and demand for life-changing treatments keep pushing the industry forward.

The future of cell and gene therapy looks promising, with the potential to revolutionize how we tackle serious diseases.